Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSBR Champions Oncology	$5.06 +0.6%	$10.15	$7.19 ▼ $14.68	$68.77M	0.39	2,239 shs	1,477 shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
OTLK Outlook Therapeutics	$8.19 -0.1%	$8.56	$4.00 ▼ $40.60	$106.58M	0.04	530,385 shs	150,455 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSBR Champions Oncology	-0.39%	-0.10%	+0.80%	-17.18%	+1.40%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	-30.02%	+260.42%
OTLK Outlook Therapeutics	-0.12%	-1.21%	-5.65%	-5.21%	-62.08%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CSBR Champions Oncology	3.2884 of 5 stars	3.3	2.0	0.0	4.6	0.0	2.5	0.0
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.8344 of 5 stars	3.4	4.0	0.0	0.0	2.8	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSBR Champions Oncology	2.50	Moderate Buy	$7.50	48.22% Upside
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	466.85% Upside

Current Analyst Ratings

Latest CSBR, OTLK, and ERYP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
3/13/2024	CSBR Champions Oncology	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSBR Champions Oncology	$53.87M	1.28	N/A	N/A	$0.34 per share	14.88
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSBR Champions Oncology	-$5.34M	-$0.72	N/A	∞	N/A	-19.76%	-850.72%	-32.62%	7/22/2024 (Estimated)
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest CSBR, OTLK, and ERYP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q3 2024	CSBR Champions Oncology	N/A	-$0.19	-$0.19	-$0.19	N/A	$12.02 million
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSBR Champions Oncology	N/A	N/A	N/A	N/A	N/A
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSBR Champions Oncology	N/A	0.60	0.60
ERYP ERYTECH Pharma	0.32	3.65	3.65
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
CSBR Champions Oncology	41.30%
ERYP ERYTECH Pharma	1.09%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
CSBR Champions Oncology	45.69%
ERYP ERYTECH Pharma	1.94%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CSBR Champions Oncology	143	13.59 million	7.38 million	Optionable
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable

CSBR, OTLK, and ERYP Headlines

Source	Headline
	Best's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positive finance.yahoo.com - April 22 at 1:21 PM
	USD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlook fxempire.com - April 22 at 1:21 PM
	WGA Releases New Housing Finance Outlook markets.businessinsider.com - April 22 at 1:21 PM
	Outlook Money’s Tushar Ghosh elevated to Publishing Director pitchonnet.com - April 22 at 1:21 PM
	Outlook: How to set up breaks between your meetings msn.com - April 22 at 1:21 PM
	Outlook Therapeutics, Inc. (OTLK) finance.yahoo.com - April 21 at 8:02 PM
	World Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbean invezz.com - April 18 at 6:25 PM
	World Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Prices finance.yahoo.com - April 18 at 6:25 PM
	Economic Outlook 2024 in Springfield connectionnewspapers.com - April 18 at 6:25 PM
	Bosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024 usnews.com - April 18 at 6:25 PM
	Reporter's Guarentee \| Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur District outlookindia.com - April 18 at 6:25 PM
	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million globenewswire.com - April 15 at 4:15 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens msn.com - April 14 at 9:03 AM
	Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot? msn.com - April 14 at 9:03 AM
	Fed's Williams: Outlook is uncertain, Fed must be data-dependent fxstreet.com - April 11 at 6:05 PM
	National Gas’ Summer Outlook 2024: Stable supply, reduced exports energylivenews.com - April 11 at 6:05 PM
	ADB Outlook forecasts 7 % GDP growth in 2025 bbs.bt - April 11 at 6:05 PM
	Natural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlook fxempire.com - April 11 at 1:44 AM
	Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut msn.com - April 11 at 1:44 AM
	Bitdefender now has identity protection for Gmail and Outlook msn.com - April 11 at 1:44 AM
	Insiders are Piling into These 10 Healthcare Stocks in 2024 finance.yahoo.com - April 10 at 3:44 PM
	Users Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fix forbes.com - April 3 at 3:14 PM
	Outlook.com trips over Google's spam blocking rules msn.com - April 3 at 3:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Champions Oncology

NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

ERYTECH Pharma

NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial